4
MARKET OVERVIEW
Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Captures industry movement, adoption patterns, and strategic signals across key end-use segments and regions.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN THE DENTAL CONSUMABLES INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE, 2022–2025
5.6.2
AVERAGE SELLING PRICE TREND OF DIFFERENT PRODUCTS, BY KEY PLAYER, 2022–2025
5.7.1
IMPORT SCENARIO (HS CODE 9018)
5.7.2
EXPORT SCENARIO (HS CODE 9018)
5.8
KEY CONFERENCES AND EVENTS, 2025–2026
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.12
IMPACT OF 2025 US TARIFF – ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON ASIA PACIFIC COUNTRIES
5.12.5
IMPACT ON END USERS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY TECHNOLOGIES/EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.5
IMPACT OF AI/GEN AI ON THE ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET
6.5.1
TOP USE CASES AND MARKET POTENTIAL
6.5.2
BEST PRACTICES FOLLOWED BY PLAYERS IN ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET
6.5.3
CASE STUDIES OF AI IMPLEMENTATION IN THE ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET
6.5.4
INTERCONNECTED/ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.5.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.4
ADOTPION BARRIERS AND INTERNAL CHALLENGES
8.5
UNMET NEEDS OF VARIOUS END USE INDUSTRIES
9
ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET, BY DISEASE (MARKET SIZE & FORECAST TO 2031 – [VALUE (USD MILLION) & VOLUME (UNITS)] 2023 TO
9.2.2
RECURRENT GINGIVITIS
9.3
CHRONIC PERIODONTITIS
9.4
AGGRESSIVE PERIODONTITIS
10
ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031 – [VALUE (USD MILLION) & VOLUME (UNITS)] 2023 TO
11
ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET, BY TREATMENT (MARKET SIZE & FORECAST TO 2031 – [VALUE (USD MILLION) & VOLUME (UNITS)] 2023 TO
11.2
NON-SURGICAL TREATMENT
11.2.3
MEDICATION THERAPY
11.2.3.2
SYSTEMIC THERAPY
11.3
FLAP SURGERY/POCKET REDUCTION THERAPY
11.6
GUIDED TISSUE REGENERATION
12
ASIA PACIFIC PERIODONTAL DISEASE TREATMENT MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031– [VALUE (USD MILLION)] 2023 TO
12.3
PRIVATE AND DSO CLINICS
12.4
ACADEMIC AND RESEARCH INSTITUTES
13
ASIA PACIFIC PERIODONTAL DISEASE TREATMENT, BY COUNTRY (MARKET SIZE & FORECAST TO 2031 – [VALUE (USD MILLION)] 2023 TO
13.2.6
REST OF ASIA PACIFIC
14.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
14.3
REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2021-2025
14.4
MARKET SHARE ANALYSIS,
14.5
BRAND/PRODUCT/TECHNOLOGY COMPARATIVE ANALYSIS
14.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.6.5.1
COMPANY FOOTPRINT
14.6.5.2
DISEASE FOOTPRINT
14.6.5.3
PRODUCT FOOTPRINT
14.6.5.4
TREATMENT FOOTPRINT
14.6.5.3
END USER FOOTPRINT
15.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
15.7.1
PROGRESSIVE COMPANIES
15.7.2
RESPONSIVE COMPANIES
15.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.8
COMPETITIVE SCENARIO
15.8.4
OTHER DEVELOPMENTS
15.9
COMPANY VALUATION AND FINANCIAL METRICS
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.4.1
KEY STRENGTHS/ RIGHT TO WIN
16.1.1.4.2
STRATEGIC CHOICES
16.1.1.4.3
WEAKNESS & COMPETITIVE THREATS
16.1.3
INSTITUT STRAUMANN AG
16.1.5
BIOLASE MG LLC. (SUBSIDIARY OF MEGA’GEN IMPLANT CO., LTD)
16.1.6
GEISTLICH PHARMA AG.
16.1.11
YOSHIDA DENTAL MFG. CO., LTD.
16.1.12
KEYSTONE DENTAL GROUP
16.1.13
ULTRADENT PRODUCTS INC.
16.2.14
BEGO GMBH & CO. KG
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.1.2
LIST OF KEY SECONDARY SOURCES
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.3
MARKET SIZE ESTIMATION FOR BASE YEAR
17.3
MARKET FORECAST APPROACH
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS
18.1
INSIGHTS FROM INDUSTRY EXPERTS
18.3
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.4
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Asia Pacific Periodontal Disease Treatment Market